These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 22992252)

  • 1. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
    Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
    Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y; Ishikawa A; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
    Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
    Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients.
    Best M; Jachiet M; Molinari N; Manna F; Girard C; Pallure V; Cosnes A; Lipsker D; Hubiche T; Schmutz JL; Le Corre Y; Cordel N; Dandurand M; Dereure O; Guillot B; Du-Thanh A; Bulai Livideanu C; Chasset F; Bouaziz JD; Francès C; Bengoufa D; Vincent T; Bessis D;
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1164-1172. PubMed ID: 29237090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.
    Ishikawa A; Muro Y; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Jul; 51(7):1181-7. PubMed ID: 22427409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in dermatomyositis-specific autoantibodies.
    Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
    Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
    Oldroyd A; Sergeant JC; New P; McHugh NJ; Betteridge Z; Lamb JA; Ollier WE; Cooper RG; Chinoy H;
    Rheumatology (Oxford); 2019 Apr; 58(4):650-655. PubMed ID: 30535395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
    Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
    J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reliability and clinical utility of Enzyme-linked immunosorbent assay for detection of anti-aminoacyl-tRNA synthetase antibody].
    Abe T; Tsunoda S; Nishioka A; Azuma K; Tsuboi K; Ogita C; Yokoyama Y; Furukawa T; Maruoka M; Tamura M; Yoshikawa T; Saito A; Sekiguchi M; Azuma N; Kitano M; Matsui K; Hosono Y; Nakashima R; Ohmura K; Mimori T; Sano H
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(2):140-4. PubMed ID: 27212600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
    Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
    Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
    Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Tincani A; Selmi C; Chan JY; Chan EK; Satoh M; Franceschini F
    Clin Exp Rheumatol; 2014; 32(6):891-7. PubMed ID: 25151986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
    Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
    Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
    Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
    Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis.
    Shimizu K; Kobayashi T; Kano M; Hamaguchi Y; Takehara K; Matsushita T
    J Dermatol; 2020 Jan; 47(1):64-68. PubMed ID: 31638280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum.
    Hall JC; Casciola-Rosen L; Samedy LA; Werner J; Owoyemi K; Danoff SK; Christopher-Stine L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1307-15. PubMed ID: 23436757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.
    Valenzuela A; Chung L; Casciola-Rosen L; Fiorentino D
    JAMA Dermatol; 2014 Jul; 150(7):724-9. PubMed ID: 24869801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease.
    Nakashima R; Hosono Y; Mimori T
    Lupus; 2016 Jul; 25(8):925-33. PubMed ID: 27252271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.
    Inoue M; Tanboon J; Hirakawa S; Komaki H; Fukushima T; Awano H; Tajima T; Yamazaki K; Hayashi R; Mori T; Shibuya K; Yamanoi T; Yoshimura H; Ogawa T; Katayama A; Sugai F; Nakayama Y; Yamaguchi S; Hayashi S; Noguchi S; Tachimori H; Okiyama N; Fujimoto M; Nishino I
    JAMA Neurol; 2020 Jul; 77(7):872-877. PubMed ID: 32310254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.